Brean Murray Carret & Co. Starts Celsion Corp (CLSN) at Buy; Expectiing Positive Phase 3 Data This Year

Brean Murray Carret & Co. initiates coverage on Celsion Corp (NASDAQ: CLSN) with a Buy. PT $7.00.

Brean analyst says, "We believe ThermoDox will be broadly adopted once it is approved. Due to the potential ability of ThermoDox to reduce the recurrence rate in intermediate HCC patients, we are optimistic about its adoption as the future standard of care, especially given how seamlessly ThermoDox can be integrated with RFA. Its effectiveness should increase the number of RFA procedures and enable the RFA/ThermoDox combination to take market share from procedures like TACE with chemotherapy. We view the use of an approved active agent (doxorubicin) as a risk mitigating factor for Celsion."

For an analyst ratings summary and ratings history on Celsion Corp click here. For more ratings news on Celsion Corp click here.

Shares of Celsion Corp closed at $1.91 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Loop Capital Starts MongoDB (MDB) at Buy, '2H Ramp Ahead'
• HSBC Starts Auna SA (AUNA) at Buy, 'Just what the doctor prescribed'
• Cantor Fitzgerald Starts Incyte (INCY) at Neutral, 'JAK-ing Up Its Pipeline In Advance of a Major Patent Cliff'